A rich and productive
pipeline of large and
small molecules

The strength of the UCB pipeline:

• Twelve novel compounds, including five large, antibody-based molecules and seven small, chemically-derived molecules, are in clinical development, addressing 16 different types of severe disease, from multiple sclerosis and Parkinson's disease to rheumatoid arthritis.

• Out of the twelve novel compounds, seven are in late stage development (Phase III or filing). UCB believes that this pipeline possesses immense potential for future growth as well as improving the quality of life for patients.

Here is an overview of all products currently being developed by UCB: